Evidence map›Paper›PMID 32117703›Full record

ArticleFrontiers in oncology2020

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better

Kristine Aasebø, Anca Dragomir, Magnus Sundström, Artur Mezheyeuski, Per-Henrik Edqvist, Geir Egil Eide, Fredrik Ponten, Per Pfeiffer, Bengt Glimelius, Halfdan Sorbye

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Loss ofEcancermedicalscience · 2024
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Kristine AasebøDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Anca DragomirDepartment of Pathology, Uppsala University Hospital, Uppsala, Sweden.
Magnus SundströmDepartment of Pathology, Uppsala University Hospital, Uppsala, Sweden.
Artur MezheyeuskiDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Per-Henrik EdqvistDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Geir Egil EideDepartment of Global Public Health and Primary Care, Lifestyle Epidemiology Group, University of Bergen, Bergen, Norway.
Fredrik PontenDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Per PfeifferDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Bengt GlimeliusDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Halfdan SorbyeDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Uppsala University · SEUniversity of Bergen · NOUppsala University Hospital · SEHaukeland University Hospital · NOOdense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

caudal type homeobox transcription factorCDX2colorectal cancermetastatic diseasepopulation basedprognosisstage 4 colorectal cancer

Identifiers

PMID32117703
PMCPMC7026487
OpenAlexW3005885288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.